Imidazopyranotacrines as Non-Hepatotoxic, Selective Acetylcholinesterase Inhibitors, and Antioxidant Agents for Alzheimer's Disease Therapy

Molecules

Volumn 21, Issue 4, 2016, Pages

  Boulebd, Houssem ^a   Ismaili, Lhassane ^b   Bartolini, Manuela ^c   Bouraiou, Abdelmalek ^a   Andrisano, Vincenza ^c   Martin, Helene ^d   Bonet, Alexandre ^d   Moraleda, Ignacio ^e   Iriepa, Isabel ^e   Chioua, Mourad ^f   Belfaitah, Ali ^a   Marco Contelles, José ^f  

^a Universite Mentouri Constantine   (Algeria)

^b UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d France   (France)

^e UNIVERSITY OF ALCALÁ   (Spain)

^f INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Alzheimer's disease; Antioxidant activity; Cholinesterase inhibitors; Hepatotoxicity; ORAC; Tacrine analogues

Indexed keywords

ANTIOXIDANT; CHOLINESTERASE INHIBITOR; IMIDAZOLE DERIVATIVE; TACRINE;

ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; HEP-G2 CELL LINE; HUMAN; LIVER; OXYGEN RADICAL ABSORBANCE CAPACITY; SYNTHESIS;

ALZHEIMER DISEASE; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; HEP G2 CELLS; HUMANS; IMIDAZOLES; LIVER; OXYGEN RADICAL ABSORBANCE CAPACITY; TACRINE;

EID: 84967180403     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21040400     Document Type: Article

References (43)

1. Soler-López, M.; Badiola, N.; Zanzoni, A.; Aloy, P. Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction. Hypothetical role of the adapter protein ECSIT in familial and sporadic Alzheimer's disease pathogenesis. Bioessays 2012, 34, 532-541. [CrossRef] [PubMed]
2. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7, 137-152. [CrossRef] [PubMed]
3. Schneider, L.S.; Mangialasche, F.; Andreasen, N.; Feldman, H.; Giacobini, E.; Jones, R.; Mantua, V.; Mecocci, P.; Pani, L.; Winblad, B.; et al. Clinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. J. Intern. Med. 2014, 275, 251-283. [CrossRef] [PubMed]
4. Ittner, L.M.; Götz, J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12, 65-72. [CrossRef] [PubMed]
5. Ávila, J. Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett. 2006, 580, 2922-2927. [CrossRef] [PubMed]
6. Rosini, M.; Simoni, E.; Milelli, A.; Minarini, A.; Melchiorre, C. Oxidative stress in Alzheimer's disease: Are we connecting the dots? J. Med. Chem. 2014, 57, 2821-2831. [CrossRef] [PubMed]
7. Murphy, S.L.; Xu, J.Q.; Kochanek, K.D. Deaths: Final Data for 2010; National Center for Health Statistics: Hyattsville, MD, USA, 2013.
8. Chacón, M.A.; Reyes, A.E.; Inestrosa, N.C. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. J. Neurochem. 2003, 87, 195-204. [CrossRef] [PubMed]
9. Terry, A.V.; Buccafusco, J.J.; Wilson, C. Cognitive dysfunction in neuropsychiatric disorders: Selected serotonin receptor subtypes as therapeutic targets. Behav. Brain Res. 2008, 195, 30-38. [CrossRef] [PubMed]
10. Gura, T. Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 2008, 14, 894. [CrossRef] [PubMed]
11. Racchi, M.; Mazzucchelli, M.; Porrello, E.; Lanni, C.; Govoni, S. Acetylcholinesterase inhibitors: Novel activities of old molecules. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2004, 50, 441-451.
12. Castro, A.; Martínez, A. Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. Curr. Pharm. Des. 2006, 12, 4377-4387. [CrossRef] [PubMed]
13. Rosini, M. Polypharmacology: The rise of multitarget drugs over combination therapies. Future Med. Chem. 2014, 6, 485-487. [CrossRef] [PubMed]
14. León, R.; García, A.G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med. Res. Rev. 2013, 33, 139-189. [CrossRef] [PubMed]
15. Romero, A.; Cacabelos, R.; Oset-Gasque, M.J.; Samadi, A.; Marco-Contelles, J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 2013, 23, 1916-1922. [CrossRef] [PubMed]
16. Reale, M.; Di Nicola, M.; Velluto, L.; D'Angelo, C.; Costantini, E.; Lahiri, D.K.; Kamal, M.A.; Yu, Q.S.; Greig, N.H. Selective acetyl and butyrylcholinesterase inhibitors reduce amyloid-beta ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: Exploring the cholinergic anti-inflammatory pathway. Curr. Alzheimer Res. 2014, 11, 608-622. [CrossRef] [PubMed]
17. Watkins, P.B.; Zimmerman, H.J.; Knapp, M.J.; Gracon, S.I.; Lewis, K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271, 992-998. [CrossRef] [PubMed]
18. Soukup, O.; Jun, D.; Zdarova-Karasova, J.; Patocka, J.; Musilek, K.; Korabecny, J.; Krusek, J.; Kaniakova, M.; Sepsova, V.; Mandikova, J.; et al. A resurrection of 7-MEOTA: A comparison with tacrine. Curr. Alzheimer Res. 2013, 10, 893-906. [CrossRef] [PubMed]
19. Zha, X.; Lamba, D.; Zhang, L.; Lou, Y.; Xu, C.; Kang, D.; Chen, L.; Xu, Y.; Zhang, L.; De Simone, A.; et al. Novel tacrine-benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, biological evaluation, and X-ray crystallography. J. Med. Chem. 2016, 59, 114-131. [CrossRef] [PubMed]
20. Martínez-Grau, A.; Marco, J.L. Friedländer reaction on 2-amino-3-cyano-4H-pyrans: Synthesis of derivatives of 4H-pyran[2,3-b]quinoline, new tacrine analogues. Bioorg. Med. Chem. Lett. 1997, 7, 3165-3170. [CrossRef]
21. Marco, J.L.; de los Ríos, C.; Carreiras, M.C.; Baños, J.E.; Badía, A.; Vivas, N.M. Synthesis and acetylcholinesterase/ butyrylcholinesterase inhibition activity of new tacrine-like analogues. Bioorg. Med. Chem. 2001, 9, 727-732. [CrossRef]
22. León, R.; Marco-Contelles, J.; García, A.G.; Villarroya, M. Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues. Bioorg. Med. Chem. 2005, 13, 1167-1175. [CrossRef] [PubMed]
23. Marco-Contelles, J.; León, R.; López, M.G.; García, A.G.; Villarroya, M. Synthesis and biological evaluation of new 4H-pyrano[2,3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause neuroprotection against calcium overload and free radicals. Eur. J. Med. Chem. 2006, 41, 1464-1469. [CrossRef] [PubMed]
24. Kaptein, B.; Kellogg, R.M.; van Bolhuis, F. Synthesis, molecular structure, and complexation of 1,4-dihydropyridines containing ligands for intramolecular complexation of metal electrophiles. Recl. Trav. Chim. Pays-Bas 1990, 109, 388-395. [CrossRef]
25. Okubo, T.; Yoshikawa, R.; Chaki, S.; Okuyama, S.; Nakazato, A. Design, synthesis and structure-affinity relationships of aryloxyanilide derivatives as novel peripheral benzodiazepine receptor ligands. Bioorg. Med. Chem. 2004, 12, 423-438. [CrossRef] [PubMed]
26. Marco-Contelles, J.; Pérez-Mayoral, E.; Samadi, A.; Carreiras, M.C.; Soriano, E. Recent Advances in the Friedländer Reaction. Chem. Rev. 2009, 109, 2652-2671. [CrossRef] [PubMed]
27. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95. [CrossRef]
28. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett. 2008, 18, 2905-2909. [CrossRef] [PubMed]
29. Cornish-Bowden, A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors (Short Communication). Biochem. J. 1974, 137, 143-144. [CrossRef] [PubMed]
30. Dávalos, A.; Gómez-Cordovés, C.; Bartolomé, B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J. Agric. Food Chem. 2004, 52, 48-54. [CrossRef] [PubMed]
31. O'Brien, P.J.; Irwin, W.; Diaz, D.; Howard-Cofield, E.; Krejsa, C.M.; Slaughter, M.R.; Gao, B.; Kaludercic, N.; Angeline, A.; Bernardi, P.; et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 2006, 80, 580-604 [CrossRef] [PubMed]
32. Schoonen, W.G.E.J.; Westerink, W.M.A.; de Roos, J.A.D.M.; Débiton, E. Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol. In Vitro 2005, 19, 505-516. [CrossRef] [PubMed]
33. Denizot, F.; Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1986, 89, 271-277. [CrossRef]
34. Dixon, M.; Webb, E.C. Enzymes, 2nd ed.; Longmans, Green and Co.: London, UK, 1964; pp. 54-166.
35. Martínez, A. Emerging Drugs and Targets for Alzheimer's Disease: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies; Royal Society of Chemistry: London, UK, 2010; Volume 2, pp. 1-24.
36. Grill, J.D.; Cummings, J.L. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev. Neurother. 2010, 10, 711-728. [CrossRef] [PubMed]
37. Haass, C. Semagacestat's fall: Where next for AD therapies? Nat. Med. 2013, 19, 1214-1215.
38. Lovestone, S.; Boada, M.; Dubois, B.; Hull, M.; Rinne, J.O.; Huppertz, H.-J.; Calero, M.; Andrés, M.V.; Gómez-Carrillo, B.; León, T.; et al. A phase II trial of tideglusib in Alzheimer's disease. J. Alzheimer's Dis. 2015, 45, 75-88.
39. Benchekroun, M.; Bartolini, M.; Egea, J.; Romero, A.; Soriano, E.; Pudlo, M.; Luzet, V.; Andrisano, V.; Jimeno, M.L.; López, M.G.; et al. Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: A synthetic renewal in tacrine-ferulic acid hybrids. Chem. Med. Chem. 2015, 10, 523-539. [CrossRef] [PubMed]
40. Nepovimova, E.; Uliassi, E.; Korabecny, J.; Pena-Altamira, L.E.; Samez, S.; Pesaresi, A.; Garcia, G.E.; Bartolini, M.; Andrisano, V.; Bergamini, C.; et al. Multitarget drug design strategy: Quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem. 2014, 57, 8576-8589. [CrossRef] [PubMed]
41. Esquivias-Pérez, M.; Maalej, E.; Romero, A.; Chabchoub, F.; Samadi, A.; Marco-Contelles, J.; Oset-Gasque, M.J. Nontoxic and neuroprotective β-naphthotacrines for Alzheimer's disease. Chem. Res. Toxicol. 2013, 26, 986-992. [CrossRef] [PubMed]
42. Chen, Y.; Sun, J.; Fang, L.; Liu, M.; Peng, S.; Liao, H.; Lehmann, J.; Zhang, Y. Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem. 2012, 55, 4309-4321. [CrossRef] [PubMed]
43. Fernández-Bachiller, M.I.; Pérez, C.; González-Muñoz, G.C.; Conde, S.; López, M.G.; Villarroya, M.; García, A.G.; Rodríguez-Franco, M.I. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem. 2010, 53, 4927-4937. [CrossRef] [PubMed]